

## References

1. Byrom B, Watson C, Doll H, et al (2018) Selection of and Evidentiary Considerations for Wearable Devices and Their Measurements for Use in Regulatory Decision Making: Recommendations from the ePRO Consortium. *Value Heal* 21:631–639. <https://doi.org/10.1016/j.jval.2017.09.012>
2. Walton MK, Cappelleri JC, Byrom B, et al (2020) Considerations for development of an evidence dossier to support the use of mobile sensor technology for clinical outcome assessments in clinical trials. *Contemp Clin Trials* 91:105962. <https://doi.org/10.1016/j.cct.2020.105962>
3. Clinical Trials Transformation Initiative (CTTI) (2017) Recommendations on developing technology derived novel endpoints. <https://www.ctti-clinicaltrials.org/projects/digital-health-technologies>.
4. DiMe Society (2020) The Playbook: Digital Clinical Measures. <https://playbook.dimesociety.org/>
5. Goldsack J, Coravos, A, Bakker JP et al (2020). Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). *npj Digit. Med.* 3, 55. <https://doi.org/10.1038/s41746-020-0260-4>
6. Diabetes Technology Society. Blood Glucose Monitoring System Surveillance Program. <https://www.diabetestechology.org/surveillance.shtml>
7. Byrom B (2021). Utilizing DHTs for Clinical Trial Endpoints. *Applied Clinical Trials* 30(5). <https://www.appliedclinicaltrialsonline.com/view/utilizing-dhts-for-clinical-trial-endpoints>